<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212887</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000685060</org_study_id>
    <secondary_id>CRUK-PH1/105</secondary_id>
    <secondary_id>CRUK-MFEz</secondary_id>
    <secondary_id>EUDRACT-2005-004085-16</secondary_id>
    <secondary_id>EU-21070</secondary_id>
    <nct_id>NCT01212887</nct_id>
  </id_info>
  <brief_title>Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer</brief_title>
  <official_title>A Cancer Research UK Phase I Trial of Adoptive Transfer of Autologous Tumor Antigen-Specific T Cells With Preconditioning Chemotherapy and Intravenous IL2 in Patients With Advanced CEA Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Research UK</source>
  <brief_summary>
    <textblock>
      RATIONALE: Placing a gene into T cells may improve the body's ability to recognize cancer&#xD;
      cells and build an immune response to fight cancer. Drugs used in chemotherapy, such as&#xD;
      cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of&#xD;
      tumor cells, either by killing the cells or by stopping them from dividing. Biological&#xD;
      therapies, such as aldesleukin, may stimulate the immune system in different ways and stop&#xD;
      cancer cells from growing. Giving specially treated T cells together with cyclophosphamide,&#xD;
      fludarabine phosphate, and aldesleukin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I clinical trial is studying the side effects and best dose of treated T&#xD;
      cells when given together with cyclophosphamide, fludarabine phosphate, and aldesleukin in&#xD;
      treating patients with cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the feasibility of MFE23 scFv-expressing autologous anti-CEA MFEz T&#xD;
           lymphocytes in combination with preconditioning chemotherapy comprising cyclophosphamide&#xD;
           and fludarabine phosphate plus aldesleukin in patients with CEA-positive tumors.&#xD;
&#xD;
        -  To assess the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  To determine the dose of MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes&#xD;
           required to give optimal survival of these cells in the circulation (recommended phase&#xD;
           II dose).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess whether MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes isolated&#xD;
           from the circulation are functional.&#xD;
&#xD;
        -  To determine the preliminary tumor response to MFE23 scFv-expressing autologous anti-CEA&#xD;
           MFEz T lymphocytes.&#xD;
&#xD;
        -  To evaluate the safety of MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of MFE23 scFv-expressing autologous&#xD;
      anti-CEA MFEz T lymphocytes.&#xD;
&#xD;
      Patients undergo leukapheresis 7-14 days before study therapy begins. Cells are then&#xD;
      transduced with a retrovirus vector and expanded to produce MFE23 scFv-expressing autologous&#xD;
      anti-CEA MFEz T lymphocytes.&#xD;
&#xD;
      Patients receive preconditioning chemotherapy comprising fludarabine phosphate IV over 15&#xD;
      minutes on days -5 to -1 or cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine&#xD;
      phosphate IV over 15 minutes on days -5 to -1. They receive MFE23 scFv-expressing autologous&#xD;
      anti-CEA MFEz T lymphocytes IV over 30 minutes on day 0. Patients also receive high-dose&#xD;
      aldesleukin IV over 15 minutes every 8 hours for up to 12 doses beginning on day 0, in the&#xD;
      absence of disease progression or unacceptable toxicity. If there is evidence of MFE23&#xD;
      scFv-expressing autologous anti-CEA MFEz T lymphocytes survival, patients may receive&#xD;
      additional high-dose aldesleukin.&#xD;
&#xD;
      Patients undergo blood sample collection periodically for pharmacokinetic and pharmacodynamic&#xD;
      studies. Some patients may undergo a tumor biopsy.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 2 weeks for 6 weeks,&#xD;
      every 4 weeks for 6 months, every 3 months for 1 year, and then every 6 months thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to safety concerns and lack of efficacy&#xD;
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients (goal is 50%) who are evaluable for MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event according to CTCAE version 3 criteria</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose of MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes that gives the highest frequency in the circulation as measured by the primary assays (recommended phase II dose)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of cells with a functional chimeric immune receptor on bCEA binding assay</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response or complete response on CT scans at 6, 12, 24, and 52 weeks as defined by RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term follow up for insertional mutagenesis</measure>
  </secondary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignancy&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
               -  Standard curative or palliative measures do not exist, are no longer effective,&#xD;
                  have been completed, or have been refused&#xD;
&#xD;
          -  CEA-positive tumor (either by immunohistochemistry or as demonstrated by elevated CEA&#xD;
             &gt; 50 μg/L)&#xD;
&#xD;
          -  No primary brain tumor or brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100 x 10^9/L&#xD;
&#xD;
          -  Neutrophil count ≥ 2.0 x 10^9/L&#xD;
&#xD;
          -  Lymphocyte count ≥ 1.0 x 10^9/L&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT/AST ≤ 5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 5 times ULN&#xD;
&#xD;
          -  Calculated creatinine clearance OR isotope clearance measurement ≥ 50 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception 4 weeks prior to, during, and for 6&#xD;
             months after completion of study therapy (male patients must use barrier-method&#xD;
             contraception)&#xD;
&#xD;
          -  LVEF ≥ 50% on MUGA scan (for patients receiving cyclophosphamide)&#xD;
&#xD;
          -  ECG and exercise ECG (or stress ECHO) normal (may be abnormal but not clinically&#xD;
             significant)&#xD;
&#xD;
          -  Urine dipstick normal (may be abnormal but not clinically significant)&#xD;
&#xD;
          -  No medical high risk due to nonmalignant systemic disease including active&#xD;
             uncontrolled infection&#xD;
&#xD;
          -  No known serologically positive hepatitis B, hepatitis C, HIV, or HTLV&#xD;
&#xD;
          -  No history of autoimmune disease&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No concurrent congestive heart failure or prior history of NYHA class III-IV cardiac&#xD;
             disease&#xD;
&#xD;
          -  No concurrent malignancies originating from other primary sites, except for adequately&#xD;
             treated cone-biopsied carcinoma in situ of the cervix uteri or basal cell or squamous&#xD;
             cell carcinoma of the skin&#xD;
&#xD;
          -  No other condition that, in the investigator's opinion, would make the patient an&#xD;
             unsuitable candidate for the clinical trial&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 30 days since prior and no concurrent participation in another clinical trial&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent radiotherapy (except for palliative&#xD;
             reasons [i.e., control of bone pain])&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent endocrine therapy, immunotherapy, or&#xD;
             chemotherapy (6 weeks for nitrosoureas and mitomycin C)&#xD;
&#xD;
          -  No toxic manifestations of previous treatment, except for alopecia or certain grade 1&#xD;
             toxicities that, in the opinion of the investigator and CRUK (Cancer Research UK),&#xD;
             would exclude the patient (e.g., grade 1 neuropathy or grade 1 fatigue)&#xD;
&#xD;
          -  No prior major thoracic and/or abdominal surgery from which the patient has not yet&#xD;
             recovered&#xD;
&#xD;
          -  No prior bone marrow transplant or extensive radiotherapy to &gt; 25% of bone marrow&#xD;
&#xD;
          -  No concurrent systemic steroids or other immunosuppressive therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy or investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert E. Hawkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>September 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2010</study_first_posted>
  <last_update_submitted>February 27, 2012</last_update_submitted>
  <last_update_submitted_qc>February 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IIIA colon cancer</keyword>
  <keyword>stage IIIB colon cancer</keyword>
  <keyword>stage IIIC colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IVB colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IIIA rectal cancer</keyword>
  <keyword>stage IIIB rectal cancer</keyword>
  <keyword>stage IIIC rectal cancer</keyword>
  <keyword>stage IVA rectal cancer</keyword>
  <keyword>stage IVB rectal cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage IIIA ovarian epithelial cancer</keyword>
  <keyword>stage IIIA ovarian germ cell tumor</keyword>
  <keyword>stage IIIB ovarian epithelial cancer</keyword>
  <keyword>stage IIIB ovarian germ cell tumor</keyword>
  <keyword>stage IIIC ovarian epithelial cancer</keyword>
  <keyword>stage IIIC ovarian germ cell tumor</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

